Skip to main content
Fig. 7 | BMC Public Health

Fig. 7

From: Targeting screening and treatment for latent tuberculosis infection towards asylum seekers from high-incidence countries – a model-based cost-effectiveness analysis

Fig. 7

Secondary analysis: incremental cost-effectiveness ratios by average numbers of secondary TB cases. The dashed lines denote the following benchmark thresholds for cost-effectiveness (from top to bottom): ~€87,600 ($100,000) – a threshold frequently utilized for health-economic analysis in the United States; ~€81,300 ($91,447), equivalent to twice the 2020 gross domestic product (GDP) per capita for Germany; ~€34,000 (£30,000) – a threshold recommended by the National Institute for Health and Care Excellence (NICE) in the United Kingdom; *The incidence threshold denotes the country-of-origin TB incidence level above which asylum seekers would become eligible for LTBI screening and TPT

Back to article page

BMC Public Health

ISSN: 1471-2458

Contact us